Stock Market Reviews

GLSI (Greenwich LifeSciences, Inc.) News

Get the latest news, insights, and market updates on GLSI (Greenwich LifeSciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
  STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on FLAMINGO-01 and the Company’s corporate strategy. Corporate Strategy The Company recently attended a Noble Capital conference on December 3, 2025,
  Dec 22, 2025 - $GLSI
• Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
  STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced an approximately 80% recurrence rate reduction in the open label non-HLA-A*02 arm of FLAMINGO-01. A preliminary analysis of recurrence rates by two methods to estimate the reduction in recur
  Dec 15, 2025 - $GLSI
• Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01
  STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the completion of enrollment in the open label non-HLA-A*02 arm of FLAMINGO-01. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are currently planned t
  Dec 8, 2025 - $GLSI
• Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
  STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date The Company has achieved a major milestone by screening over 1,000 patients in Flamingo-01, continuing its screening r
  Dec 3, 2025 - $GLSI
• Several Insiders Invested In Greenwich LifeSciences Flagging Positive News
  Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
  Nov 14, 2025 - $GLSI
• Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
  STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Austria. The Company's application to European regulators has been formally approved, adding Austria as an approved country in FLAMINGO-01 in a
  Oct 9, 2025 - $GLSI
• Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
  STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Belgium. The Company's application to European regulators has been formally approved, adding Belgium as an approved country in FLAMINGO-01 in a
  Oct 2, 2025 - $GLSI
• Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
  STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Portugal. The Company's application to European regulators has been formally approved, adding Portugal as an approved country in FLAMINGO-01 i
  Sep 30, 2025 - $GLSI
• Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland
  STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Ireland. The Company's application to European regulators has been formally approved, adding Ireland as an approved country in FLAMINGO-01 in
  Sep 18, 2025 - $GLSI
• Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
  STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that FDA has granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population. The designation specifically states that "GLSI-100 for the treatment of patients with HLA-A*02 g
  Sep 10, 2025 - $GLSI